![conference banner](/images/conference-banner.jpeg)
Abstract
Introduction: Zhilong Huoxue Tongyu capsule (ZLHX) is a traditional Chinese medicinal compound preparation, which exhibits obvious therapeutic effects on aspirin resistance (AR). However, the mechanism of ZLHX on AR is rarely reported.
Objectives: This study aimed to explore the therapeutic effects of AR and the underlying mechanisms of ZLHX on AR rats.
Methods: An AR model was established through treatment with a high-fat, high-sugar, and highsalt diet for 12 weeks and oral administration of aspirin (27 mg/kg/day) and ibuprofen (36 mg/kg/day) in weeks 9-12. The rats were administrated with ZLHX (225, 450, and 900 mg/kg) from week 12 to week 16. Blood samples were collected after the experiment. Thromboelastography analysis was performed, and the levels of triglyceride (TG), total cholesterol (TC), lowdensity lipoprotein cholesterol (LDL-C), and high-density lipoprotein cholesterol (HDL-C) were determined. Furthermore, the levels of thromboxane B2 (TXB2) and 6-keto-prostaglandin F1α (6- keto-PGF1α) were determined with commercial ELISA kits. Finally, the gene expressions of microRNA- 126-3p (miRNA-126-3p) and miRNA-34b-3p were detected through a real-time quantitative polymerase chain reaction.
Results: Results demonstrated that ZLHX significantly inhibited platelet aggregation in the AR rats. Moreover, ZLHX markedly decreased the levels of TC, TG, and LDL-C and increased the level of HDL-C. Meanwhile, ELISA results confirmed that ZLHX can elevate the expression levels of TXB2 and 6-keto-PGF1α. Further studies suggested that ZLHX significantly downregulated the expression levels of miRNA-126-3p and miRNA-34b-3p.
Conclusion: This study revealed that the therapeutic effect of ZLHX might be related to the regulation of lipid metabolism and the miRNA pathway.
Keywords: Zhilong huoxue tongyu capsule, aspirin resistance, ELISA, lipid metabolism, miRNA, cardiovascular disease.
[http://dx.doi.org/10.1016/j.autrev.2017.07.009] [PMID: 28705781]
[http://dx.doi.org/10.1038/s41569-021-00552-1] [PMID: 33958774]
[http://dx.doi.org/10.1155/2021/5563987] [PMID: 34367302]
[http://dx.doi.org/10.1161/STROKEAHA.119.026917] [PMID: 31390963]
[http://dx.doi.org/10.1016/j.amjcard.2016.12.004] [PMID: 28139223]
[http://dx.doi.org/10.1111/1471-0528.13914] [PMID: 26929162]
[http://dx.doi.org/10.1016/j.pharmthera.2011.01.011] [PMID: 21295071]
[http://dx.doi.org/10.1016/j.ijcard.2016.06.104] [PMID: 27372038]
[http://dx.doi.org/10.1016/j.jacc.2017.04.041] [PMID: 28619197]
[http://dx.doi.org/10.3389/fcvm.2021.702110] [PMID: 34422929]
[http://dx.doi.org/10.1016/j.bcp.2017.06.123] [PMID: 28636884]
[http://dx.doi.org/10.1038/s41598-019-49123-y] [PMID: 31511539]
[http://dx.doi.org/10.1016/j.pharmthera.2013.08.005] [PMID: 23993980]
[http://dx.doi.org/10.1016/j.exger.2013.03.008] [PMID: 23562841]
[http://dx.doi.org/10.1016/j.atherosclerosissup.2015.02.004] [PMID: 25936298]
[http://dx.doi.org/10.1161/hc3401.093152] [PMID: 11514380]
[PMID: 1792655]
[http://dx.doi.org/10.1111/j.1538-7836.2005.01338.x] [PMID: 16194198]
[http://dx.doi.org/10.1016/j.thromres.2013.03.005] [PMID: 23522855]
[http://dx.doi.org/10.1016/j.thromres.2014.01.029] [PMID: 24525312]
[http://dx.doi.org/10.1016/j.bbrc.2009.11.005] [PMID: 19896465]
[http://dx.doi.org/10.1172/JCI62185] [PMID: 23543060]
[http://dx.doi.org/10.1161/CIRCRESAHA.114.303784] [PMID: 24657879]
[http://dx.doi.org/10.1159/000366312] [PMID: 25200830]
[http://dx.doi.org/10.1161/CIRCULATIONAHA.112.094524] [PMID: 22811578]
[http://dx.doi.org/10.1160/TH12-03-0211] [PMID: 22782083]
[http://dx.doi.org/10.1055/s-0039-1692681] [PMID: 31266078]
[http://dx.doi.org/10.3389/fphys.2021.652579] [PMID: 33935804]
[http://dx.doi.org/10.3390/jpm11060508] [PMID: 34199723]
[http://dx.doi.org/10.1093/eurheartj/eht032] [PMID: 23391580]
[http://dx.doi.org/10.1172/jci.insight.93344]
[http://dx.doi.org/10.1038/nm.3487] [PMID: 24584117]
![Wayfinder Image](/images/wayfinder.jpg)